Progress in Antisense Therapeutics Discovery and Development
- 28 September 2007
- book chapter
- Published by Wiley
- Vol. 209, 158-168
- https://doi.org/10.1002/9780470515396.ch12
Abstract
Progress in the discovery and development of antisense therapeutics continues at a rapid pace. Detailed understanding of the pharmacokinetic, toxicological and pharmacological properties of phosphorothioate oligonucleotides is now available. Further, an ever-increasing body of information is available about new and improved chemical classes of antisense drugs that are progressing toward clinical trials.Keywords
This publication has 7 references indexed in Scilit:
- Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinaseNature Medicine, 1996
- Progress in Antisense Oligonucleotide TherapeuticsAnnual Review of Pharmacology and Toxicology, 1996
- Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administrationBiochemical Pharmacology, 1995
- Delivery of Oligonucleotides and PolynucleotidesJournal of Drug Targeting, 1995
- Radiolabeling of Methylphosphonate and Phosphorothioate Oligonucleotides and Evaluation of Their Transport in Everted Rat Jejunum SacsPharmaceutical Research, 1995
- A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital wartsClinical Pharmacology & Therapeutics, 1994